After this evening's -3.6% drop to $140.03 per share, Moderna might just keep moving past its target price of $144.36. With an average analyst rating of buy, and target prices from $62.0 to $310.0, the stock's next move is anyone's guess.
Moderna has an average level of shares sold short, at 7.4% of its total share float. The stock's short ratio (also called days to cover) is 6.26. The company's insiders own 9.57% of its outstanding shares, which indicates a strong alignment between management and shareholder interests.
Institutional investors own 73.4% of Moderna's shares, which indicates they have a high level of confidence in the company.
Institutions Invested in Moderna
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2024-03-31 | Baillie Gifford and Company | 12% | 44,655,817 | $6,253,153,999 |
| 2024-03-31 | Vanguard Group Inc | 10% | 39,036,872 | $5,466,333,138 |
| 2024-03-31 | Blackrock Inc. | 7% | 25,395,878 | $3,556,184,765 |
| 2024-03-31 | State Street Corporation | 4% | 14,452,035 | $2,023,718,443 |
| 2024-03-31 | FMR, LLC | 4% | 13,599,837 | $1,904,385,158 |
| 2024-03-31 | Flagship Pioneering Inc. | 3% | 9,666,038 | $1,353,535,289 |
| 2024-03-31 | Theleme Partners LLP | 2% | 7,321,797 | $1,025,271,224 |
| 2024-03-31 | Geode Capital Management, LLC | 2% | 6,750,479 | $945,269,566 |
| 2024-03-31 | Wellington Management Group, LLP | 1% | 5,604,703 | $784,826,554 |
| 2024-03-31 | Morgan Stanley | 1% | 5,493,965 | $769,319,912 |
